HomeCompareMPGPY vs PFE

MPGPY vs PFE: Dividend Comparison 2026

MPGPY yields 10.94% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $8.4K in total portfolio value· pulled ahead in Year 10
10 years
MPGPY
MPGPY
● Live price
10.94%
Share price
$4.14
Annual div
$0.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.2K
Annual income
$2,170.59
Full MPGPY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MPGPY vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMPGPYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MPGPY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MPGPY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MPGPY
Annual income on $10K today (after 15% tax)
$929.87/yr
After 10yr DRIP, annual income (after tax)
$1,845.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $20,474.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MPGPY + PFE for your $10,000?

MPGPY: 50%PFE: 50%
100% PFE50/50100% MPGPY
Portfolio after 10yr
$45.4K
Annual income
$14,214.65/yr
Blended yield
31.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MPGPY
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
7.6
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MPGPY buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMPGPYPFE
Forward yield10.94%6.13%
Annual dividend / share$0.45$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$41.2K$49.6K
Annual income after 10y$2,170.59$26,258.71
Total dividends collected$16.2K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: MPGPY vs PFE ($10,000, DRIP)

YearMPGPY PortfolioMPGPY Income/yrPFE PortfolioPFE Income/yrGap
1$11,794$1,093.96$9,153$693.39+$2.6KMPGPY
2$13,825$1,205.81$8,593$849.25+$5.2KMPGPY
3$16,114$1,321.02$8,336$1,066.78+$7.8KMPGPY
4$18,681$1,438.99$8,437$1,384.80+$10.2KMPGPY
5$21,548$1,559.09$9,013$1,875.40+$12.5KMPGPY
6$24,737$1,680.69$10,306$2,680.72+$14.4KMPGPY
7$28,272$1,803.21$12,820$4,101.38+$15.5KMPGPY
8$32,177$1,926.05$17,673$6,826.70+$14.5KMPGPY
9$36,478$2,048.68$27,543$12,591.86+$8.9KMPGPY
10← crossover$41,202$2,170.59$49,560$26,258.71$8.4KPFE

MPGPY vs PFE: Complete Analysis 2026

MPGPYStock

PageGroup plc, together with its subsidiaries, provides recruitment consultancy and other ancillary services in the United Kingdom, rest of Europe, the Middle East, Africa, the Asia Pacific, and the Americas. The company offers executive search services under the Page Executive brand; recruitment services for qualified professional on permanent, temporary, and contract or interim basis under the Michael Page brand; recruitment services to organizations requiring permanent employees and temporary or contract staff at technical and administrative support, professional clerical, and junior management levels under the Page Personnel brand; and flexible recruitment outsourcing services under the Page Outsourcing brand. It also provides assessment, consulting, and talent services under the Page Assessment, Page Consulting, and Page Talent supplementary brands. The company was formerly known as Michael Page International plc and changed its name to PageGroup plc in June 2016. PageGroup plc was founded in 1976 and is headquartered in Addlestone, the United Kingdom.

Full MPGPY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MPGPY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MPGPY vs SCHDMPGPY vs JEPIMPGPY vs OMPGPY vs KOMPGPY vs MAINMPGPY vs JNJMPGPY vs MRKMPGPY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.